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Noninvasive InVivo Magnetic Resonance Measures of
Glutathione Synthesis in Human and Rat Liver as an
Oxidative Stress Biomarker
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Daniel S. Vidler,1,4 Matthew Clemence,5 Peter G. Blain,1,4 Roy Taylor,1,2 Michael P. Gamcsik,6* and
Peter E. Thelwall1,2*
Oxidative stress (OS) plays a central role in the progression of liver disease and in damage to liver
by toxic xenobiotics. We have developed methods for noninvasive assessment of hepatic OS
defenses bymeasuring flux through the glutathione (GSH) synthesis pathway. 13C-labeled GSH is
endogenously produced and detected by in vivo magnetic resonance after administration of
[2-13C]-glycine. We report on a successful first-ever human demonstration of this approach as
well as preclinical studies demonstrating perturbed GSH metabolism in models of acute and
chronic OS. Human studies employed oral administration of [2-13C]-glycine and 13C spectros-
copy on a 3T clinical magnetic resonance (MR) imaging scanner and demonstrated detection and
quantification of endogenously produced 13C-GSH after labeled glycine ingestion. Plasma analy-
sis demonstrated that glycine 13C fractional enrichment achieved steady state during the 6-hour
ingestion period. Mean rate of synthesis of hepatic 13C-labeled GSH was 0.326 0.18 mmole/kg/
hour. Preclinical models of acute OS and nonalcoholic steatohepatitis (NASH) comprised CCl4-
treated and high-fat, high-carbohydrate diet-fed Sprague-Dawley rats, respectively, using intrave-
nous administration of [2-13C]-glycine and observation of 13C-label metabolism on a 7T preclini-
cal MR system. Preclinical studies demonstrated a 54% elevation of GSH content and a 31%
increase in flux through the GSH synthesis pathway at 12 hours after acute insult caused by CCl4
administration, as well as a 23% decrease in GSH content and evidence of early steatohepatitis in
the model of NASH. Conclusion: Our data demonstrate in vivo 13C-labeling and detection of
GSH as a biomarker of tissue OS defenses, detecting chronic and acute OS insults. The methods
are applicable to clinical research studies of hepatic OS in disease states over time as well as moni-
toring effects of therapeutic interventions. (HEPATOLOGY 2014;59:2321-2330)
See Editorial on Page 2077
T
issue oxidative stress (OS) results from an
excess of reactive oxygen species (ROS), result-
ing in an inability of cells to maintain a
reduced intracellular environment. Hepatic OS is cen-
tral to the processes involved in progression of liver
disease,1-3 and the cell has evolved multiple mecha-
nisms to protect itself from OS, including DNA
repair, enzymes that catalyze the deactivation of free
radicals, and antioxidants of endogenous or dietary
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origin. ROS and pro-oxidants can arise within a tissue
from multiple endogenous and exogenous sources,
such as by-products of oxidative phosphorylation,
components of an immune response, from xenobiotics,
or the generation of reactive intermediates as a result
of catabolic processes.1 The principal hepatic intracel-
lular antioxidant is glutathione (GSH), a tripeptide of
glycine, cysteine, and glutamate that is synthesized
in two steps from its constituent amino acids by
c-glutamylcysteine synthetase and GSH synthetase.3,4
GSH has a central role in protecting the cell against
ROS, and in detoxifying xenobiotics. Homeostatic
processes strive to maintain hepatic GSH content and
maintain a reduced intracellular environment.
A wealth of preclinical studies have investigated
hepatic responses to OS by change in GSH content or
GSH synthesis enzyme activities.5 In addition, blood-
based indirect markers of OS have been identified,
typically comprising by-products of OS (e.g., lipid per-
oxidation [LPO] by-products),6-8 along with measure-
ments in liver biopsy samples of GSH content,
enzyme activities, and expression of genes related to
OS defense, as reported on previously.9,10 However,
direct tissue sampling is invasive and carries an associ-
ated risk to the patient, and blood biomarkers report
on downstream effects of OS rather than providing
direct measures of cellular redox defenses.
We have developed methods to monitor liver GSH
metabolism in vivo, providing a noninvasive biomarker
that reports directly on hepatic OS defences. In our
previous studies, we have demonstrated that adminis-
tration of 13C-labeled glycine results in the metabolic
production of c-glutamylcysteinyl-[2-13C]-glycine
(referred to hereafter as 13C-GSH), and that in vivo
monitoring of this 13C-labeling process can be per-
formed by magnetic resonance imaging (MRI).11-13 In
this study, we translate this approach to the human
liver for clinical research studies and show alterations
in GSH metabolism in response to chronic and acute
OS insults in preclinical models.
Our preclinical studies employed two models of
hepatic OS: an acute insult resultant from CCl4
administration and chronic OS generated from a high-
fat, high-carbohydrate (HFHC) diet model of steatohe-
patitis. CCl4 administration has been widely employed
to generate hepatic OS and study hepatotoxicity, fibrosis,
hepatocellular death, and carcinogenicity14 and allows us
to gauge change in hepatic GSH turnover after acute OS
insult. Our diet-induced steatohepatitis model was based
on that described by Kohli et al.15 as a model of chronic
OS, which exhibited a nonalcoholic steatohepatitis
(NASH) phenotype. Our model comprised an 8-week
diet duration, with the aims of producing early NASH
and testing whether our magnetic resonance (MR)
approach can detect changes in tissue OS defenses at this
stage of NASH progression.
The aim of our study was to translate the GSH
13C-labeling approach to human studies, to perform
preclinical studies of controlled acute and chronic OS
insult, and thus demonstrate the utility of GSH
metabolism monitoring as a biomarker of perturbed
hepatic redox defences suitable for application to clini-
cal research studies.
Materials and Methods
Preclinical Study: Experimental Design. Preclini-
cal studies were performed under a project license
granted by the Home Office in accord with the Animals
(Scientific Procedures) Act of 1986. [2-13C]-Glycine
was purchased from Cambridge Isotope Laboratories,
Inc. (Andover, MA) and from Sigma-Aldrich Co. Ltd.
(Gillingham, UK). Three groups of male Sprague-
Dawley rats (Charles River UK, Ltd., Margate, UK)
comprised control, CCl4-induced acute OS, and rats
fed an HFHC diet to induce steatohepatitis (n5 7 per
group). CCl4-treated rats received a 1:1 mixture of
CCl4 and refined olive oil (0.1 mL per 100 g body
weight, intraperitoneal [IP] injection) at 12 hours before
the MR study. The HFHC diet comprised ad libitum
feed containing 60% kcal from fat (TestDiet 58R2; IPS
Ltd., London, UK) and drinking water supplemented
with 55 mmol/L of sucrose and 128 mmol/L of fruc-
tose for 8 weeks before MR experiments.
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Preclinical Study: Magnetic Resonance
Spectroscopy. Figure 1A shows the relative timing
of [2-13C]-glycine infusion and MR data acquisi-
tions. MR studies were started at the same time each
day (10 a.m.) to avoid the influence of diurnal varia-
tion in GSH synthesis rate on study data.16 Rats
were anesthetized with IP-administered solution of
fentanyl (0.79 mg/mL), fluanisone (2.5 mg/mL), and
midazolam (1.25 mg/mL) in water at a dose of 0.2
mL/kg, and maintenance doses were administered as
required through an MR-compatible IP cannula.
Intravenous (IV) administration of [2-13C]-glycine in
water (1 M, pH 7.4) was through a tail vein cathe-
ter. Respiratory and body temperature monitoring
was performed during MR experiments. 1H-
decoupled 13C spectra were acquired on a Varian 7T
magnet and spectrometer (DirectDrive system; Var-
ian, Inc., Palo Alto, CA) using a custom 13C/1H
coil (15 mm diameter 13C coil; Fig. 2A). Positioning
of the coil relative to the liver is shown in Fig.
2C,E. 13C spectra were acquired every 10 minutes
for the experiment duration (tip angle5 90 degrees;
repetition time [TR]5 1.5 seconds; spectral width
[SW]5 10 kHz; 400 averages). [2-13C]-glycine deliv-
ery commenced after acquisition of baseline MR
data at a loading dose of 4 mmoles/kg/hour for 90
minutes, then at a maintenance dose of 1 mmole/kg/
hour for 5 hours. Details of preparation of liver tis-
sue perchloric acid extracts, of proton nuclear mag-
netic resonance (1H NMR) and mass spectrometry
(MS) analysis of liver and plasma samples, prepara-
tion of histological section, and MR data analysis
and quantitation are provided in the Supporting
Materials. Statistical significance of differences in
concentrations and rates between experimental groups
was determined using one-way analysis of variance
with Tukey’s multiple comparisons (Minitab 16;
Minitab Inc., State College, PA).
Human Study: Subjects and Experimental
Design. Ethical permission for the study was obtained
from the Newcastle and North Tyneside 1 Research
Ethics Committee. Healthy male volunteers (n5 3)
were recruited from the staff of Newcastle University
(Newcastle upon Tyne, UK) and informed consent
was obtained. Subjects abstained from alcohol for 3
days before the study and fasted from 11.30 p.m. on
the evening before the study (water ad libitum). The
study commenced at 8.30 a.m. the following day with
acquisition of baseline liver 13C spectra. Figure 1B
shows timing of [2-13C]-glycine administration, blood
sampling, and MR examinations. [2-13C]-glycine was
purchased from Cambridge Isotope Laboratories,
administration consisted of 12 doses of 3 g of [2-13C]-
glycine dissolved in 50 mL of water, ingested orally at
30-minute intervals over a 6-hour period. Glycine
administration commenced immediately after acquisi-
tion of baseline liver MR spectra and MR data acquisi-
tion and was repeated at 2, 4, 6, and 8 hours. Plasma
samples were stored at 240C before analysis of total
and [2-13C]-labeled glycine content by 1H NMR, as
described in the Supporting Materials. Volunteers ate a
standardized lunch (comprising a sandwich, an apple,
and water) at 165 minutes after commencing glycine
ingestion. The experimental protocol was designed
to replicate the preclinical studies as closely as possible,
though [2-13C]-glycine administration was oral
instead of by IV infusion. This provided delivery of
label to the liver through the portal vein and repre-
sented a pragmatic approach for ethical review com-
mittee consideration of this first-ever healthy volunteer
study.
Human Study: 13C Magnetic Resonance Spectro-
scopy. MRI and spectroscopy (MRS) measurements
were made using a Philips Achieva 3T whole-body
scanner (Philips Medical Systems, Best, The Nether-
lands) and an in-house 13C/1H surface coil (12 cm
diameter 13C coil; Fig. 2B) positioned over the liver. A
representative image showing positioning of the 13C
coil is shown in Fig. 2D,F. 13C spectra were acquired
using a pulse-acquired sequence with 1H WALTZ
decoupling (TR5 1.5 seconds; nominal tip angle5 90
degrees; 1,024 data points; 8-kHz SW; 15-minute scan
duration). Concentrations of 13C-labeled metabolites
were determined from spectra as described in the Sup-
porting Materials.
Fig. 1. MR study protocol summary. (A) Preclinical study protocol
showing timings of glycine infusion and MRI scanning. (B) Human
study protocol showing timings of blood sampling, oral glycine admin-
istration, and MRI scanning.
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Results
Preclinical Studies: Perturbed GSH Turnover
Is Observed After Acute and Chronic OS Insults.
Table 1 shows rat morphometric measurements, plasma
biochemical analysis, and hepatic F2-isoprostane content
analysis. CCl4 treatment resulted in a significant eleva-
tion of plasma aspartate aminotransferase (AST) and
alanine aminotransferase (ALT), relative to the control
Fig. 2. 13C/1H RF coils, and MR images showing coil positioning. (A and B) 13C/1H RF coils employed for preclinical and human studies,
respectively. (C-F) Representative hepatic 1H images showing location of 13C surface coils (dashed line) for preclinical (C and E) and human
(D and F) studies.
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group, indicative of acute liver damage (P< 0.05).
Quantitation of hepatic F2-isoprostanes as a biomarker
of LPO demonstrated significant elevation in both the
CCl4-treated and HFHC diet groups, compared to con-
trol, indicating OS insults.
Figure 3 shows 13C spectra and calculated metabo-
lite concentrations from the preclinical experimental
studies. Figure 3A shows a representative rat hepatic
13C spectrum acquired at 6 hours after commence-
ment of [2-13C]-glycine administration. Resonances
from infused [2-13C]-glycine and endogenously pro-
duced 13C-labeled GSH are clearly observed at 42.4
and 44.2 parts per million (ppm), respectively, adja-
cent to natural-abundance 13C resonances from lipids
in the 35-14-ppm region. The highlighted region of
this spectrum (50-40 ppm) is shown in Fig. 3B, com-
prising representative spectra from the three experi-
mental groups acquired at the 5-hour experimental
time point, showing the [2-13C]-glycine and 13C-GSH
resonances. Differences in both 13C-GSH and [2-13C]-
glycine concentration are apparent between the groups,
reflecting insult-induced differences in both GSH and
glycine metabolism.
Dynamic measurements of hepatic 13C-labeled GSH
content were made over the experimental time course
and are shown, for the three groups, in Fig. 3C. A
marked, statistically significant (P< 0.05) elevation of
13C-GSH content was observed in the CCl4-treated
group, compared to the other groups (1.716 0.39,
compared to 1.116 0.19, mmol/L for the control
group at 5 hours), consistent with hepatic response to
the acute OS insult. Conversely, rats in the HFHC
diet group showed slightly lower 13C-GSH than the
control group (0.866 0.18 mmol/L), indicating a
lower GSH turnover, though this difference was not
statistically significant. However, total GSH content
was significantly lower than control in the HFHC
group, and significantly elevated in the CCl4-treated
Table 1. Preclinical Study Morphometric Measurements, Plasma Biochemical Analysis,
and Hepatic Isoprostane Content Analysis
Body Mass (g) Liver Mass (g) ALT (U/L) AST (U/L) ALP (U/L)
Hepatic Isoprostane Content (ng/g)
F2-III F2-IV F2-VI
Control 2206 33 10.86 0.8 496 8 716 6 2906 17 1.46 0.3 0.066 0.19 1.76 0.2
CCl4 2436 27 11.66 0.8 3786 84 9506 378 2816 27 46.76 10.9 0.906 0.19 36.46 3.2
HFHC diet 5276 67 17.06 3.1 746 34 2006 140 1366 43 20.26 2.8 0.606 0.14 5.76 1.3
Abbreviation: ALP, alkaline phosphatase.
Fig. 3. Preclinical study 13C MR data. (A) Representative hepatic 13C spectrum acquired after 6 hours of [2-13C]-glycine infusion. (B) Regions
of the 13C spectrum showing resonances from [2-13C]-glycine and 13C-labeled GSH from rats in each of the three study groups. (C) Time course
of hepatic 13C-labeled GSH concentration in the experimental groups. (D) Mean concentrations of 13C-labeled and total GSH in the experimental
groups at the end of the 6.5-hour experiment. (E and F) Time courses of hepatic [2-13C]-glycine and [2-13C]-serine concentration in the experi-
mental groups.
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group (P< 0.05; Fig. 3D). The data demonstrate the
model of early NASH exhibiting compromised OS
defenses (with consequent potential for cellular dam-
age), in contrast to the acute CCl4 insult, resulting in
a strong up-regulation of GSH production. The rate
of 13C-label incorporation into the hepatic GSH
pool also reflects these group differences, showing a
higher rate for CCl4-treated rats than for the other
groups, with an initial rate (measured between t5 30
and 90 minutes) of 0.766 0.14 mmoles/kg/hour,
compared to 0.586 0.09 and 0.486 0.07 mmoles/kg/
hour for the control and HFHC groups, respectively
(P< 0.05).
Hepatic [2-13C]-glycine content over the experiment
duration is shown in Fig. 3E, charting the effect of
label infusion. All three groups show a similar pattern:
a rapid rise during the initial 90-minute high infusion
rate, followed by maintenance of [2-13C]-glycine con-
centration at approximately 4 mmol/L. The infusion
scheme was chosen to rapidly maximize and then
maintain hepatic glycine 13C fractional enrichment.
Minor differences between groups are observed after
approximately 3 hours; the CCl4-treated group shows
a downward trend in [2-13C]-glycine concentration
from 2 to 6 hours, whereas the HFHC diet group
shows a slight upward trend. 1H MRS measurements
of glycine 13C fractional enrichment in extract samples
were 57%6 4%, 59%6 5%, and 69%6 2% in the
control, CCl4-treated, and HFHC groups, respectively,
at the end of the infusion period, with the HFHC
group measurement significantly different from control
(P< 0.05). We attribute these differences to variations
in flux through the glycine metabolism pathways: In
addition to alterations in flux of 13C label to GSH, we
also observed differences in flux through serine hydrox-
ymethyltransferase (SHMT) to 13C-labeled serine. Our
preclinical study protocol did not permit serial sam-
pling of plasma to measure glycine 13C fractional
enrichment, but previous studies by Macdonald
et al.11 and by Fern and Garlick17 demonstrate that a
similar infusion of labeled glycine results in steady
state being achieved rapidly and within 2 hours, and
our human studies demonstrated glycine fractional
enrichment reaching steady state within 2 hours
(vide infra).
Figure 3F shows hepatic [2-13C]-serine content,
with the CCl4-treated group showing an elevated con-
centration of labeled serine, compared to the other
groups. This difference was statistically significantly,
compared to control, at the 1.5-hour time point and
compared to the HFHC group at the 1.5-, 3-, and 5-
hour time points (P< 0.05).
Figure 4 shows histological sections from the three
groups stained with hematoxylin and eosin (H&E),
alpha-smooth muscle actin (a-SMA) for myofibroblast
visualisation, and Sirius Red as a marker of collagen
deposition. Liver histology was normal for the control
group, whereas the CCl4 treatment group showed hall-
marks of acute OS (ballooned and swollen dead or
dying hepatocytes and the emergence of hepatic myofi-
broblasts). The HFHC group showed early steatohepa-
titis, including fat deposition, activation of hepatic
myofibroblasts, and collagen deposition.
MS analysis of GSH tissue extracts identified a frac-
tion of the GSH containing two 13C nuclei per mole-
cule. We have observed similar labeling in our
previous studies of tumour OS defenses13 and attribute
this to synthesis of 13C-label in the cysteinyl residue of
GSH. Incorporation of 13C label from [2-13C]-glycine
into cysteine occurs through the trans-sulfuration path-
way,18 with labeled serine as an intermediate. The per-
centage of doubly 13C-labeled GSH was
2.9%6 0.8%, 4.1%6 1.7%, and 6.2%6 1.6% for
the control, CCl4-treated, and HFHC diet groups,
respectively. The HFHC group showed a significantly
higher degree of double 13C-labeling than the other
groups (P< 0.05), indicating higher production of cys-
teine through the trans-sulfuration pathway. This may
originate from dietary differences between groups,
with lower protein intake in the HFHC group result-
ing in up-regulation of trans-sulfuration to supply
cysteine.18
Fig. 4. Histological sections of rat liver from the preclinical study
groups. (A-C) H&E-stained sections. (D-F) a-SMA stained sections and
Sirius Red–stained sections (inset). Representative photomicrographs
at 1003 magnification of a minimum of n5 3 rats per group. Black
arrow indicates damaged hepatocytes, yellow arrow indicates fat depo-
sition, red arrow indicates a-SMA staining of myofibroblasts, and blue
arrows indicate collagen deposition.
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Human Studies: Hepatic 13C-Labeled GSH Can
Be Detected and Quantified After Ingestion of
[2-13C]-Glycine. Study participants were male and
had an average age of 326 4 years and a body weight
of 756 3 kg. Standard plasma clinical biochemistry
assays reported normal results for all participants.
Hepatic 13C spectra showed well-resolved resonances
from [2-13C]-glycine and 13C-GSH, allowing quantifi-
cation of 13C-label incorporation into GSH over the
experimental time course. Figure 5A shows spectra
from a participant acquired before and at 6 hours after
commencement of [2-13C]-glycine ingestion. The spec-
trum was similar in appearance to the preclinical stud-
ies (reflecting the similarities in experimental
approach), though a broader region of the spectrum
was observed as a result of the lower magnetic field
strength of the human whole-body scanner (3T, rather
than 7T). Figure 5B shows the 65-35-ppm spectra
region from the same subject at the five experimental
time points, showing the administered [2-13C]-glycine
and its subsequent metabolism. Signal from labeled
glycine was observed at the first measurement after
ingestion (2 hour), and its magnitude was maximal at
the end of the 6-hour ingestion period. Incorporation
of the 13C label into the 2-carbon of the glycinyl resi-
due of GSH (44.2 ppm) and into other metabolites of
glycine was also observed from the 2-hour time point
onward. These other metabolites included [2-13C]-
and [3-13C]-serine at 57.4 and 61.3 ppm, respectively,
choline and/or creatine at 54.8 ppm, and a resonance
at 45.8 ppm that may originate from intermediates in
the formation of creatine and choline, guanidoacetate,
or dimethylglycine. Figure 5C-E shows the mean
Fig. 5. Human study 13C MR data. (A) Hepatic 13C spectra from a study volunteer before and after the 6-hour glycine ingestion period.
(B) Region of the 13C spectrum from a study volunteer showing resonances from [2-13C]-glycine and endogenously 13C-labeled GSH, serine, and
creatine. (C-E) Mean concentrations of [2-13C]-glycine, 13C-labeled GSH, and [2-13C]-serine over the experimental time course.
Fig. 6. Human study plasma glycine analysis. (A) Mean 13C
fractional enrichment of plasma glycine. (B) Mean glycine (unlabeled
plus labeled) concentration over the experimental time course.
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concentrations of 13C-labeled glycine, GSH, and serine
in human liver over the experimental time course. The
data demonstrate the rapid turnover of GSH, and
rapid flux of glycine to serine, with the appearance of
both by the 2-hour time point and appreciable drop
in concentration 2 hours after ingestion of [2-13C]-gly-
cine had ceased (8-hour time point).
Figure 6 shows the 13C fractional enrichment and
total concentration of plasma glycine in the human
studies. 13C fractional enrichment was constant at
64.0%6 6.6% during the glycine ingestion period.
This indicates that steady-state labeling was achieved,
and thus the incorporation of 13C label into GSH
reflects the flux through the GSH pathway, rather than
the changing 13C-labeling of the glycine pool. The
concentration of plasma glycine peaked at 1.86 0.7
mM at the 6-hour time point.
The initial rate of incorporation of 13C label into
GSH, measured between the 0- and 2-hour time
points, was 0.326 0.18 mmol/kg/hour. The highest
concentrations of 13C-labeled metabolites were
observed at the end of the [2-13C]-glycine administra-
tion period; peak hepatic [2-13C]-glycine concentration
was 2.36 1.5 mmol/L, whereas 13C-GSH and
[2-13C]-serine concentrations were 1.06 0.4 and
1.36 0.6 mmol/L, respectively.
Discussion
13C MRS Provides a Repeatable Noninvasive
In Vivo Measure of GSH Synthetic Rate. Our data
demonstrate successful quantitation of endogenously
produced 13C-labeled GSH in human liver and per-
turbed GSH concentration and turnover rate in rodent
models of acute and chronic hepatic OS. The noninva-
sive nature of MR provides a safe, repeatable tool
applicable to hepatic clinical research, avoiding the
need for biopsy sampling. A broad range of bio-
markers have been employed in numerous preclinical
and clinical studies to report on OS. Those centred on
GSH include GSH content, activities of enzymes
involved in GSH synthesis and adduct formation, and
concentrations of other cellular antioxidants and activ-
ities of their associated enzymes.5,19-22 However, GSH
concentration and enzyme activity measurements do
not necessarily reflect flux through GSH synthesis and
utilization pathways, and small differences in the bal-
ance between GSH synthesis and utilization may
underlie the literature conflict on, for example,
whether CCl4 causes an acute increase or decrease in
GSH content.4,22,23 In this regard, our dynamic 13C-
labeling approach may afford a useful, robust metric
for assessment of cellular response to hepatic OS by
reporting on flux, rather than steady-state concentra-
tions of GSH.
Although our method does not distinguish between
reduced and oxidized GSH (because the chemical shift
of the 13C label is unaffected by GSH redox state),
our data demonstrate that changes in hepatic GSH
turnover and content provide a sensitive redox defense
biomarker. Future work using a labeling scheme of a
13C nucleus close to the GSH thiol group may allow
the reduced and oxidized forms of GSH to be distin-
guished. The present studies were conducted using
[2-13C]-glycine because this compound is well toler-
ated at elevated concentrations, having a 13C resonance
distinct from other resonances in the spectrum
and, unlike cysteine, is not rate limiting for GSH syn-
thesis.5 A method to measure GSH synthesis by incor-
poration of 3H-labeled cysteine into GSH has been
previously employed in clinical research studies.24,25
Our method has some similarities in approach, but
has the advantage of providing a direct, dynamic, and
radiolabel-free tissue GSH content measurement.
Performance of 13C MRS is not a standard capabil-
ity for the majority of MRI scanners in current use.
However, all major MRI scanner manufacturers have
3T scanner products capable of 13C spectroscopy, and
appropriate radiofrequency (RF) coils are commercially
available. We consider our technique most suited to
clinical research studies at present (where human appli-
cation of 13C MRS has played an important role to
date), and precedents exist for translation of 13C MR
to use in clinical diagnosis.26 The cost of [2-13C]-gly-
cine for our studies was twice the cost of per-volunteer
access to the MR scanner and thus not prohibitive for
clinical research. Furthermore, refinement of the exper-
imental protocol to use lower quantities of 13C label
(by lower total dose or shorter administration period)
may be possible given the achieved spectral quality.
The higher variance in label incorporation into GSH
in humans, compared with the preclinical studies, may
reflect greater interindividual biological variation and/
or differences in methodology (oral vs. IV label admin-
istration). However, the variance in human 13C-GSH
synthesis rates was similar to that observed in other
studies with similar methodological approaches, such
as measurement of human hepatic glycogen synthesis
rate, as reported on previously.27
Brain glutathione content measurements have been
made by 1H MRS.28,29 This approach is well suited to
normal and neoplastic brain tissue, but is unable to
report on GSH flux and performs less well in other
tissues as a result of shorter T2 relaxation times and
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significant contributions to the 1H spectrum from lip-
ids. A recent and novel MR approach has employed
dynamic nuclear polarization (DNP) methods to mea-
sure the equilibrium flux between 13C-labeled ascorbic
and dehydroascorbic acid as an in vivo probe of tissue
redox state.30,31 DNP provides a method to greatly
increase the MR signal from an exogenously adminis-
tered compound, such as 13C-labeled ascorbate, and
permits measurement of enzyme flux over a short (tens
of seconds) time scale. However, the approach requires
administration of considerable quantities of 13C-
labeled tracer, which may have the potential to alter
redox balance. In our studies, we employed conven-
tional 13C spectroscopy, permitting measurements of
GSH metabolism over a 6.5-hour time period and
using a tracer molecule that can be administered with-
out altering the rate of GSH synthesis.5
Hepatic OS Results in Significant Perturbation of
GSH Turnover, Measurable by Noninvasive 13C
MRS. Our human studies represent the translation of
a novel methodology with potential for direct quanti-
tation of GSH content and synthesis rate in humans
as a biomarker. Studies of biopsy samples have demon-
strated decreased GSH content in nonalcoholic fatty
liver disease (NAFLD) and NASH patients10,32 (a
finding echoed by our preclinical data) and have inves-
tigated the effect of therapeutic regimes.33 Our nonin-
vasive approach provides a direct measurement from
liver tissue (as compared with indirect blood bio-
markers) without the need for invasive biopsy. The
preclinical models of acute and chronic OS exhibited
insult impact in tissue histology, plasma biomarker
assay results, MS analysis of isoprostane content, and
in 13C MR measures of glycine and GSH metabolism.
A major acute OS insult with adaptive changes in
GSH concentration and turnover was produced by
CCl4 administration, whereas a mild chronic insult
with evidence of compromised OS defenses and early
histological signs of steatohepatitis was produced in
the HFHC dietary model. F2-isoprostanes provide a
biomarker of LPO and thus tissue OS,34 and elevated
concentrations have been reported in patients with
NAFLD35 and in rat models of hepatic fibrosis.36 The
elevated levels observed in the CCl4-treated and
HFHC diet groups provides confirmation that the
experimental insults resulted in hepatic OS.
The CCl4-treated group exhibited an approximately
50% increase in GSH concentration and 13C label
incorporation rate, reflecting a cellular response of
increased GSH synthesis and utilization. We chose to
perform our MR studies at 12 hours after CCl4
administration to coincide with a large impact on tis-
sue OS and cellular response to the insult,37 and the
significant effect of the insult was also observed in the
biochemical and histological measurements.
Previous studies using the HFHC dietary model of
NASH have demonstrated florid NASH developing
over a 16-week period.15 Our studies employed an 8-
week HFHC dietary feeding period, and isoprostane
analysis and histology confirmed hepatic OS and the
appearance of a NASH phenotype in our experimental
group at the end of this period. Our studies were lim-
ited to an 8-week duration, in part, by the animal-size
constraints imposed by our preclinical MR scanner.
Decreased hepatic GSH content was observed in this
group, along with elevated flux through the trans-
sulfuration pathway and decreased SHMT flux. Future
studies to investigate the progression of the HFHC
dietary model to florid NASH beyond the stage
employed in our studies would provide information
on the changing hepatic OS environment and resultant
cellular adaptations.
In summary, our data demonstrate in vivo 13C-label-
ing and noninvasive detection of GSH after ingestion
(human) or IV infusion (rat) of [2-13C]-glycine. Clini-
cal research applications for this novel methodology
include directly quantifying the effect of GSH-depleting
xenobiotics, such as acetaminophen, drugs that elevate
GSH synthesis rate by supply of rate-limiting substrate,
such as N-acetyl cysteine or S-adenosyl methionine, and
of disease processes involving OS and perturbed hepatic
OS defences, such as steatohepatitis.
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